Somatostatin analogues as therapeutics in retinal disease

Pharmacology and Therapeutics

Volumn 122, Issue 3, 2009, Pages 324-333

  Vasilaki, Anna ^a   Thermos, Kyriaki ^b  

^a Faculty of Medicine   (Greece)

^b Faculty of Medicine   (Greece)

Author keywords

Neuropeptide; Neuroprotectant; Retinal disease; Somatostatin; Therapeutics

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; BEVACIZUMAB; BIM 23745; BIM 23926; CORTISTATIN; CYCLIC GMP; CYN 154806; DOPAMINE; L 779976; L 817818; NEUROPEPTIDE; NITRIC OXIDE; OCTREOTIDE; PEGAPTANIB; RANIBIZUMAB; RUBOXISTAURIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RELEASE INHIBITORY FACTOR; SOMATOSTATIN RELEASE INHIBITORY FACTOR AGONIST; SOMATOSTATIN RELEASE INHIBITORY FACTOR CAMPTOTHECIN CONJUGATE; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; CELL DEATH; CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE PAIN; HUMAN; INFLAMMATION; INTRAOCULAR PRESSURE; ISCHEMIA; LASER COAGULATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA CELL; RETINA DETACHMENT; RETINA DISEASE; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINA NERVE CELL; REVIEW; RISK FACTOR; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TRAUMATIC CATARACT; TREATMENT PLANNING; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

ANIMALS; HUMANS; RETINAL DISEASES; SOMATOSTATIN;

EID: 67349173142     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.03.010     Document Type: Review

References (173)

1. Adamis A.P., Miller J.W., Bernal M.-T., D'Amico D.J., Folkman J., Yeo T.-K., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118 (1994) 445-450
2. Afzal A., Shaw L.C., Ljubimov A.V., Boulton M.E., Segal M.S., and Grant M.B. Retinal and choroidal microangiopathies: therapeutic opportunities. Microvasc Res 74 (2007) 131-144
3. Ahern G.P., Klyachko V.A., and Jackson M.B. cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO. Trends Neurosci 25 (2002) 510-517
4. Aiello L.P. Targeting intraocular neovascularization and edema - one drop at a time. N Engl J Med 359 (2008) 967-969
5. ++ currents in rod and cone photoreceptors of the salamander retina. J Neurosci 20 (2000) 929-936
6. Alderton W.K., Cooper C.E., and Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem J 357 (2001) 593-615
7. Ambati J., Chalam K.V., Chawla D.K., D'Angio C.T., Guillet E.G., Rose S.J., et al. Elevated gamma aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 115 (1997) 1161-1166
8. Arena S., Pattarozzi A., Corsaro A., Schettini G., and Florio T. Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways. Mol Pharmacol 19 (2005) 255-267
9. Averbukh E., Halpert M., Yanko R., Yanko L., Peèr J., Levinger S., et al. Octreotide, a somatostatin analogue, fails to inhibit hypoxia-induced retinal neovascularization in the neonatal rat. Int J Exp Diabetes Res 1 (2000) 39-47
10. Bagnoli P., Dal Monte M., and Casini G. Expression of neuropeptides and their receptors in the developing retina of mammals. Histol Histopathol 18 (2003) 1219-1242
11. Baldysiak-Figiel A., Lang G.K., Kampmeier J., and Lang G.E. Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia. J Endocrinol 180 (2004) 417-424
12. Barabás P., Kovács I., Kovács R., Pálhalmi J., Kardos J., and Schousboe A. Light-induced changes in glutamate release from isolated rat retina is regulated by cyclic guanosine monophosphate. J Neurosci Res 67 (2002) 149-155
13. Barber A.J. A new view of diabetic retinopathy: a neurodegerative disease of the eye. Prog Neuro-Psychophacol Biol Psychiatry 27 (2003) 283-290
14. Barber A.J., Lieth E., Khin S.A., Antonetti D.A., Buchanan A.G., and Gardner T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102 (1998) 783-791
15. Bezerra Y., Fuselier J.A., Peyman G.A., Oner H., Drouant G., and Coy D.H. Study of inhibitory effects of an antiangiogenic somatostatin-camptothecin conjugate on laser-induced choroidal neovascularization in rats. Retina 25 (2005) 345-354
16. Bigiani A., Petrucci C., Ghiaroni V., Dal Monte M., Cozzi A., Kreienkamp H.J., et al. Functional correlates of somatostatin receptor 2 overexpression in the retina of mice with genetic deletion of somatostatin receptor 1. Brain Res 1025 (2004) 177-185
17. Bocci G., Culler M.D., Fioravanti A., Orlandi P., Fasciani A., Colucci R., et al. In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. Eur J Clin Invest 37 (2007) 700-708
18. Boehm B.O., Lang G.K., Jehle P.M., Feldman B., and Lang G.E. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 33 (2001) 300-306
19. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179 (1973) 77-79
20. Bredt D.S., and Snyder S.H. Nitric oxide, a novel neuronal messenger. Neuron 8 (1992) 3-11
21. Bringmann A., Reichenbach A., and Wiedemann P. Pathomechanisms of cystoid macular edema. Ophthalmic Res 36 (2004) 241-249
22. Buchi E.R., Suivaizdis I., and Fu J. Pressure-induced retinal ischemia in rats: an experimental model for quantitative study. Ophthalmologica 203 (1991) 138-147
23. Campochiaro P.A. Retinal and choroidal neovascularization. J Cell Physiol 184 (2000) 301-310
24. Carrasco E., Hernández C., de Torres I., Farrés J., and Simó R. Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Mol Vis 14 (2008) 1496-1502
25. Carrasco E., Hernández C., Miralles A., Huguet P., Farrés J., and Simó R. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 30 (2007) 2902-2908
26. Casini G., Catalani E., Dal Monte M., and Bagnoli P. Functional aspects of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retinal disease. Histol Histopathol 20 (2005) 615-632
27. Catalani E., Cervia D., Martini D., Bagnoli P., Simonetti E., Timperio A.M., et al. Changes in neuronal response to ischemia in retinas with genetic alterations of somatostatin receptor expression. Eur J Neurosci 25 (2007) 1447-1459
28. Celiker U., Ilhan N., Ozercan I., Demir T., and Celiker H. Octreotide reduces ischaemia-reperfusion injury in the retina. Acta Ophthalmol Scand 80 (2002) 395-400
29. Cervia D., Casini G., and Bagnoli P. Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol Cell Endocrinol 286 (2008) 112-122
30. Chen C.H., and Chen S.C. Evidence of the presence of specific vascular endothelial growth factor in fetal bovine retina. Exp Cell Res 169 (1987) 287-295
31. Choi Y.B., Tenneti L., Le D.A., Ortiz J., Bai G., Chen H.S., et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci 3 (2000) 15-21
32. Clemens A., Klevesath M.S., Hofmann M., Raulf F., Henkels M., Amiral J., et al. Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. Metabolism 48 (1999) 1236-1240
33. Colquitt J.L., Jones J., Tan S.C., Takeda A., Clegg A.J., and Price A. Ranibizuamb and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 12 (2008) iii-iv, ix-201
34. Cousin M.A., Hurst H., and Nicholls D.G. Presynaptic calcium channels and field-evoked transmitter exocytosis from cultured cerebellar granule cells. Neuroscience 81 (1997) 151-161
35. Cuilla T.A., Amador A.G., and Zinman B. Diabetic retinopathy and diabetic macular edema. Diabetic Care 26 (2003) 2653-2664
36. Dal Monte M., Cammalleri M., Martini D., Casini G., and Bagnoli P. Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: results from transgenic mice. Invest Ophthalmol Vis Sci 48 (2007) 3480-3489
37. 2 somatostatin receptor in the mouse retina. N-S Arch Pharmacol 367 (2003) 188-192
38. Dal Monte M., Petrucci C., Vasilaki A., Cervia D., Grouselle D., Epelbaum J., et al. Genetic deletion of somatostatin receptor 1 alters somatostatinergic transmission in the mouse retina. Neuropharmacology 45 (2003) 1080-1092
39. Das Evcimen N., and King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 55 (2007) 498-510
40. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 10 (2004) 61-85
41. Davis M.I., Wilson S.H., and Grant M.B. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Horm Metab Res 33 (2001) 295-299
42. Dawson T.M., Bredt D.S., Fotuhi M., Hwang P.M., and Snyder S.H. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc Nat Acad Sci USA 88 (1991) 7797-7801
43. de Lecea L., Criado J.R., Prospero-Garcia O., Gautvik K.M., Schweitzer P., Danielson P.E., et al. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 381 (1996) 242-245
44. DeVries S.H., and Schwartz E.A. Modulation of an electrical synapse between solitary pairs of catfish horizontal cells by dopamine and second messengers. J Physiol 414 (1989) 351-375
45. Ding J.D., and Weinberg R.J. Distribution of soluble guanylyl cyclase in rat retina. J Comp Neurol 500 (2007) 734-745 (Corrected and republished in: J Comp Neurol 502, 734-745
46. Dowling J.E. The Retina (1987), Harvard University Press
47. Ferrara N., Damico L., Shams N., Lowman H., and Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 (2006) 859-870
48. Ferreira I.L., Duarte C.B., Neves A.R., and Carvalho A.P. Culture medium components modulate retina cell damage induced by glutamate, kainate or "chemical ischemia". Neurochem Int 32 (1998) 387-396
49. Ferriero D.M. Developmental expression of somatostatin receptors in the rat retina. Brain Res Dev Brain Res 67 (1992) 309-315
50. Ferriero D.M., and Sagar S.M. Development of somatostatin immunoreactive neurons in rat retina. Dev Brain Res 34 (1987) 207-214
51. Fine S.I., Berger K.W., Maguire M.G., and Ho A.C. Age-related macular degeneration. New Engl J Med 342 (2000) 483-492
52. Florio T., Morini M., Villa V., Arena S., Corsaro A., Thellung S., et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144 (2003) 1574-1584
53. Forloni G., Lucca E., Angeretti N., Chiessa R., and Vezzani A. Neuroprotective effect of somatostatin on nonapoptotic NMDA-induced neuronal death: role of cyclic GMP. J Neurochem 68 (1997) 319-327
54. García de la Torre N., Wass J.A.H., and Turner H.E. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol 57 (2002) 425-441
55. Gehlbach P., and Purple R.L. Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion. Invest Ophthalmol Vis Sci 35 (1994) 669-676
56. Goldstein I.M., Ostwald P., and Roth S. Nitric oxide: a review of its role in retinal function and disease. Vis Res 36 (1996) 2979-2994
57. Gow A.J., Chen Q., Gole M., Themistocleous M., Lee V.M., and Ischiropoulos H. Two distinct mechanisms of nitric oxide-mediated neuronal cell death show thiol dependency. Am J Physiol 278 (2000) C1099-C1107
58. Grant M.B. Insulin like growth factor-I in diabetic vascular complications. Curr Opin Endocrinol Diabetes 3 (1996) 335-345
59. Grant M.B., Caballero S., and Millard W.J. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept 48 (1993) 267-278
60. Grant M.B., and Caballerom S. Somatostatin analogues as drug therapies for retinopathies. Drugs Today (Barc) 38 (2002) 783-791
61. Grant M.B., Mames R.N., Fitzgerald C., Hazariwala K.M., Cooper-DeHoff R., Caballero S., et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23 (2000) 504-509
62. Green A.R., Hainsworth A.H., and Jackson D.M. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology 39 (2000) 1483-1494
63. Guillemin R. Somatostatin: the beginnings, 1972. Mol Cell Endocrinol 286 (2008) 3-4
64. Haverkamp S., and Eldred W.D. Localization of nNOS in photoreceptor, bipolar and horizontal cells in turtle and rat retinas. Neuroreport 9 (1988) 2231-2235
65. Hernaez-Ortega M.C., Soto-Pedre E., and Martin J.J. Sandostatin LAR for cystoid diabetic macular edema: a 1-year experience. Diabetes Res Clin Pract 64 (2004) 71-72
66. Higgins R.D., Yan Y., and Schrier B.K. Somatostatin analogues inhibit neonatal retinal neovascularisation. Exp Eye Res 74 (2002) 553-559
67. Hogewind B.F., Pieters G., and Hoyng C.B. Octreotide acetate in dominant cystoid macular dystrophy. Eur J Ophthalmol 18 (2008) 99-103
68. Holtkamp G.M., Kijlstra A., Peek R., and de Vos A.F. Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes. Prog Retin Eye Res 20 (2001) 29-48
69. Hoyer D., Bell G.I., Berelowitz M., Epelbaum J., Feniuk W., Humphrey P.P.A., et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 16 (1995) 86-88
70. Jager R.D., Mieler W.F., and Miller J.W. Age-related macular degeneration. N Engl J Med 358 (2008) 2606-2617
71. Janssen J., and Lamberts S. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol 52 (2000) 1-9
72. Janssen J.A., Jacobs M.L., Derkx F.H., Weber R.F., van der Lely A.J., and Lamberts S.W. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82 (1997) 2809-2815
73. Jayakar S.S., and Dikshit J. AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs. Int J Neurosci 6 (2004) 695-734
74. Johnson J., Rickman D.W., and Brecha N.C. Somatostatin and somatostatin subtype 2A expression in the mammalian retina. Microsci Res Tech 50 (2000) 103-111
75. Kamisaki Y., Hamahashi T., Mita C., and Itoh T. D-2 dopamine receptors inhibit release of aspartate and glutamate in rat retina. J Pharmacol Exp Ther 256 (1991) 634-638
76. Kiagiadaki F., and Thermos K. Effect of intravitreal administration of somatostatin and sst2 analogues on AMPA-induced neurotoxicity in rat retina. Invest Ophth Vis Sci 49 (2008) 3080-3089
77. Kiagiadaki F., Koulakis E., and Thermos K. Dopamine (D1) receptor activation and nitrinergic agents influence somatostatin levels in rat retina. Exp Eye Res 86 (2008) 18-24
78. Kirkegaard C., Norgaard K., Snorgaard O., Bek T., Larsen M., and Lund-Andersen H. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinol (Copenh) 122 (1990) 766-772
79. Kitaoka Y., Kumai T., Isenoumi K., Kitaoka Y., Motoki M., Kobayashi S., et al. Neuroprotective effect of nitric oxide against NMDA-induced neurotoxicity in the rat retina is associated with tyrosine hydroxylase expression. Brain Res 977 (2003) 46-54
80. +2/calmodulin-dependent nitric oxide synthase and a soluble guanylyl cyclase in vertebrate photoreceptor cells. EMBO J 13 (1994) 3312-3320
81. Kouvidi E., Papadopoulou-Daifoti Z., and Thermos K. Somatostatin modulates dopamine release in rat retina. Neurosci Lett 391 (2006) 82-86
82. Kowluru R.A., Engerman R.L., Case G.L., and Kern T.S. Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int 38 (2001) 385-390
83. Kuijpers R.W., Baarsma S., and van Hagen P.M. Treatment of cystoid macular edema with octreotide. N Engl J Med 338 (1998) 624-626
84. Lambooij A.C., Kuijpers R.W., van Lichtenauer-Kaligis E.G., Kliffen M., Baarsma G.S., van Hagen P.M., et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 41 (2000) 2329-2335
85. Lei S., Jackson M.F., Jia Z., Roder J., Bai D., Orser B.A., et al. Cyclic GMP-dependent feedback inhibition of AMPA receptors is independent of PKG. Nat Neurosci 3 (2000) 559-565
86. Lieth E., Barber A.J., Xu B., Dice C., Ratz M.J., Tanase D., et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes 47 (1998) 815-820
87. Lieth E., Gardner T.W., Barber A.J., Antonetti D.A., and Penn State Retina Research Group. Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 28 (2000) 3-8 (Comment in: Clin Experiment Ophthalmol 28, 1-2)
88. Lipton S.A. Ischemic cell death in brain neurons. Physiol Rev 79 (1999) 1431-1568
89. Lipton A.J., Johnson M.A., MacDonald T., Lieberman M.W., Gosal D., and Gaton B. S-nitrothiols signal the ventilatory response to hypoxia. Nature 413 (2001) 171-174
90. Lipton S.A., and Rosenberg P.A. Excitatory amino acids as a final commot pathway in neurologic disorders. N Engl J Med 330 (1994) 613-622
91. Lu C., and McMahon D.G. Modulation of hybrid bass retinal gap junctional channel gating by nitric oxide. J Physiol 499 (1997) 689-699
92. Luo Q., Peyman G.A., Conway M.D., and Woltering E.A. Effect of a somatostatin analog (octreotide acetate) on the growth of retinal pigment epithelial cells in culture. Curr Eye Res 15 (1996) 909-913
93. Lutty G., Grunwald J., Majji A.B., Uyama M., and Yoneya S. Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. Mol Vis 5 (1999) 35
94. Mallet B., Vialettes B., Haroche S., Escoffier P., Gastaut P., Taubert J.P., et al. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metab 18 (1992) 438-444
95. Manzoni O., Prezeau L., Marin P., Deshager S., Bockaert J., and Fagni L. Nitic oxide-induced blockade of NMDA receptors. Neuron 8 (1992) 653-662
96. Mastrodimou N., Kiagiadaki F., and Thermos K. The role of nitric oxide and cGMP in somatostatin's protection of retinal ischemia. Invest Ophthalmol Vis Sci 49 (2008) 342-349
97. Mastrodimou N., Kiagiadaki F., Hodjarova M., Karagianni E., and Thermos K. Somatostatin receptors (sst2) regulate cGMP production in rat retina. Regul Pept 133 (2006) 41-46
98. Mastrodimou N., Lambrou G.N., and Thermos K. Effect of somatostatin analogues on chemically induced ischaemia in the rat retina. N-S Arch Pharmacol 371 (2005) 44-53
99. Mastrodimou N., Vasilaki A., Papadioti A., Low M.J., Hoyer D., and Thermos K. Somatostatin receptors in wildtype and somatostatin deficient mice and their involvement in nitric oxide physiology in the retina. Neuropeptides 40 (2006) 365-373
100. McCombe M., Lightman S., Eckland D.J., Hamilton A.M., and Lightman S.L. Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. Eye 5 (1991) 569-575
101. McLeod D.S., Crone S.N., and Lutty G.A. Vasoproliferaton in the neonatal dog model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 37 (1996) 1322-1333
102. McLeod D.S., Lutty G.A., Wajer S.D., and Flower R.W. Visualization of a developing vasculature. Microvasc Res 33 (1987) 257-269
103. McMahon D.G., and Ponomareva L.V. Nitric oxide and cGMP modulate retinal glutamate receptors. J Neurophysiol 76 (1996) 2307-2315
104. Meads C., Salas C., Roberts T., Moore D., Fry-Smith A., and Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Asses 7 (2001) 9
105. 2+ current modulated by cGMP-dependent protein kinase. Nature 369 (1994) 336-339
106. Michaelson I. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 68 (1948) 137-180
107. Miller J.W., Adamis A.P., Shima D.T., D'Amore P.A., Moulton R.S., O'Reilly M.S., et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular antiongenesis in a primate model. Am J Pathol 145 (1994) 574-584
108. Mills S.L., and Massey S.C. Differential properties of two gap junctional pathways made by AII amacrine cells. Nature 377 (1995) 734-737
109. Missotten T., van Laar J.A., van der Loos T.L., van Daele P.L., Kuijpers R.W., Baarsma G.S., et al. Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. Am J Ophthalmol 144 (2007) 838-843
110. Møller L.N., Stidsen C.E., Hartmann B., and Holst J.J. Somatostatin receptors. Biochim Biophys Acta 1616 (2003) 1-84
111. Mori M., Aihara M., and Shimizu T. Differential expression of somatostatin receptors in the rat eye: sstR4 is intensely expressed in the iris/ciliary body. Neurosci Lett 223 (1997) 185-188
112. Moseley H., Foulds W.S., Allan D., and Kyle P.M. Routes of clearance of radioactive water from the rabbit vitreous. Br J Ophthalmol 68 (1984) 145-151
113. Mosinger J.L., Price M.T., Bai H.Y., Xiao H., Wozniak D.F., and Olney J.W. Blockade of both NMDA and non-NMDA receptors is required for optimal protection against ischemic neuronal degeneration in the in vivo adult mammalian retina. Exp Neurol 113 (1991) 10-17
114. + siphoning and water transport in rat retinal Muller cells is mediated by a coenrichment of Kir4.1 and AQP4 in specific membrane domains. Glia 26 (1999) 47-54
115. National Institute for Clinical Excellence. Guidance on the use of photodynamic therapy for age-related macular degeneration. Technology Appraisal Guidance London NICE (2003) 68
116. Nelson E.J., Connoly J., and McArthur P. Nitric oxide and S-nitrosylation: excitotoxic and cell signaling mechanism. Biol Cell 95 (2003) 3-8
117. Olias G., Viollet C., Kusserow H., Epelbaum J., and Meyerhof W. Regulation and function of somatostatin receptors. J Neurochem 89 (2004) 1057-1091
118. Osborne N.N., Block F., and Sontag K.H. Reduction of ocular blood flow results in glial fibrillary acidic protein (GFAP) expression in rat retinal muller cells. Vis Neurosci 7 (1991) 637-639
119. Osborne N.N., Casson R.J., Wood J.P., Chidlow G., Graham M., and Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 23 (2004) 91-147
120. Osborne N.N., Wood J.P., Cupido A., Melena J., and Chidlow G. Topical flunarizine reduces IOP and protects the retina aginaist ischemia-excitotoxicity. Invest Ophth Vis Sci 43 (2002) 1456-1464
121. Palii S.S., Caballero S., Shapiro G., and Grant M.B. Medical treatment of diabetic retinopathy with somatostatin analogues. Expert Opin Investig Drugs 16 (2007) 73-82
122. Palii S.S., Afzal A., Shaw L.C., Pan H., Caballero S., Miller R.C., et al. Nonpeptide somatostatin receptor agonists specifically targeting ocular neovascularization via the somatostatin type 2 receptor. Invest Ophthalmol Vis Sci 49 (2008) 5094-5102
123. Papadaki T., Tsilimbaris M., Thermos K., Karavellas M., Samonakis D., Papapdakis A., et al. The role of lanreotide in the treatment of choroidal neovascularization secondary to age-related macular degeneration. A Pilot Clinical Trial. Retina-J Ret Vit Dis 23 (2003) 799-807
124. Papadaki T., Zacharopoulos I., Iaccheri B., Fiore T., and Foster C.S. Somatostatin for uveitic cystoid macular edema (CME). Ocul Immunol Inflamm 13 (2005) 469-470
125. Pemp B., and Schmetterer L. Ocular blood flow in diabetes and age-related macular degeneration. Can J Ophthalmol 43 (2008) 295-301
126. Petrucci C., Resta V., Fieni F., Bigiani A., and Bagnoli P. Modulation of potassium current and calcium influx by somatostatin in rod bipolar cells isolated from the rabbit retina via sst2 receptors. N-S Arch Pharmacol 363 (2001) 680-694
127. Pocock J.M., and Nicholls D.G. Exocytotic and nonexocytotic modes of glutamate release from cultured cerebellar granule cells during chemical ischaemia. J Neurochem 70 (1998) 806-813
128. Porta M., and Allione A. Current approaches and perspectives in the medical treatment of diabetic retinopathy. Pharmacol Ther 103 (2004) 167-177
129. Reiner P.B., Laycock A.G., and Doll C.J. A pharmacological model of ischemia in the hippocampal slice. Neurosci Lett 119 (1990) 175-178
130. Rohrer S.P., Birzin E.T., Mosley R.T., Berk S.C., Hutchins S.M., Shen D.M., et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282 (1998) 737-740
131. Roufail E., Stringer M., and Rees S. Nitric oxide synthase immunoreactivity and NADPH diaphorase staining are co-localised in neurons closely associated with the vasculature in rat and human retina. Brain Res 684 (1995) 36-46
132. Sall J.W., Klisovic D.D., O'Dorisio M.S., and Katz S.E. Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. Exp Eye Res 79 (2004) 465-476
133. 3H]D-aspartate from cultured chick retina cells. Neurochem Res 21 (1996) 361-368
134. Schmetterer L., and Polak K. Role of nitric oxide in the control of ocular blood flow. Prog Ret Eye Res (2001) 823-847
135. Schulz S., Handel M., Schreff M., Schmidt H., and Hollt V. Localisation of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies. J. Physiol (Paris) 94 (2000) 259-264
136. Schwarcz R., and Coyle J.T. Kainic acid: neurotoxic effects after intraocular injection. Invest Ophth Vis Sci 16 (1977) 141-148
137. Schwartz-Bloom R.D., and Sah R. γ-Aminobutyric acid. A neurotransmission and cerebral ischemia. J Neurochem 77 (2001) 353-371
138. Shapiro B., Kronheim S., and Pinistone B. The presence of immunoreactive somatostatin in the rat retina. Horm Metab Res 11 (1979) 79-80
139. Shumak S.L., Grossman L.D., Chew E., Kozousek V., George S.R., Singer W., et al. Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study. Clin Invest Med 13 (1990) 287-292
140. Simó R., Carrasco E., Fonollosa A., Garcia-Arumi J., Casamitjana R., and Hernandez C. Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 30 (2007) 725-727
141. Simó R., Lecube A., Sararols L., Garcia-Arumi J., Segura R.M., and Hernandez C. Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients. Diabetes Care 25 (2002) 2282-2286
142. Smith G.G., and Baird C.D. Survival time of retinal cells when deprived of their blood supply by increased intraocular pressure. Am J Ophthalmol 35 (1952) 133-136
143. Smith L.E., Kopchick J.J., Chen W., Knapp J., Kinose F., Daley D., et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276 (1997) 1706-1709
144. Spoerri P.E., Caballero S., Wilson S.H., Shaw L.C., and Grant M.B. Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Invest Ophthalmol Vis Sci 44 (2003) 365-369
145. Spranger J., Bühnen J., Jansen V., Krieg M., Meyer-Schwickerath R., Blum W.F., et al. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 (correction of IFG-BP3) in proliferative diabetic retinopathy. Horm Metab Res 32 (2000) 196-200
146. Spranger J., Mohlig M., Osterhoff M., Buhnen J., Blum W.F., and Pfeiffer A.F. Retinal photocoagulation does not influence intraocular levels of IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy-evidence for combined treatment of PDR with somatostatin analogues and retinal photocoagulation?. Horm Metab Res 33 (2001) 312-316
147. Spraul C.W., Baldysiak-Figiel A., Lang G.K., and Lang G.E. Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefes Arch Clin Exp Ophthalmol 240 (2002) 227-231
148. Spraul C.W., Kaven C.K., Kampmeier J.K., Lang G.K., and Lang G.E. Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro. Curr Eye Res 19 (1999) 483-490
149. Stephanson E., Wilson C.A., Schoen T., and Kuwabara T. Experimental ischemia induces cell mitosis in the adult rat retina. Invest Ophthalmol Vis Sci 29 (1988) 1050-1055
150. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 85 (2005) 845-881
151. Tannenbaum, G.S., & Epelbaum, J. (2000). Somatostatin In: Handbook of Physiology. Vol V, Section 7: The Endocrine System, Hormonal Control of Growth. (J.L. Kostyo, Vol. Ed., H.M. Goodman, Section Ed.). Oxford University Press, NY, Oxford, 221-265.
152. Thermos K. Functional mapping of somatostatin receptors in the retina: a review. Vis Res 43 (2003) 1805-1815
153. Thermos K. Novel signals mediating the functions of somatostatin: the emerging role of NO/cGMP. Mol Cell Endocrinol 286 (2008) 49-57
154. Thermos K., and Reisine T. Somatostatin receptor subtypes in the clonal anterior pituitary cell lines AtT-20 and GH3. Mol Pharmacol 33 (1988) 370-377
155. Thermos K., Bagnoli P., Epelbaum J., and Hoyer D. The somatostatin sst1 receptor: an autoreceptor for somatostatin in brain and retina?. Pharmacol Ther 110 (2006) 455-464
156. Thermos K., He H.T., Wang H., Margolis N., and Reisine T. Biochemical properties of brain somatostatin receptors. Neurosci 31 (1989) 131-141
157. van Hagen P.M., Baarsma G.S., Mooy C.M., Ercoskan E.M., ter Averst E., Hofland L.J., et al. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 143 Suppl 1 (2000) S43-S51
158. van Wijngaarden P., Coster D.J., and Williams K.A. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293 (2005) 1509-1513
159. Vasilaki A., Gardette R., Epelbaum J., and Thermos K. NADPH-diaphorase colocalization with somatostatin receptor subtypes sst2A and sst2B in the retina. Invest Ophthalmol Vis Sci 42 (2001) 1600-1609
160. Vasilaki A., Mouratidou M., Schulz S., and Thermos K. Somatostatin influences nitric oxide production in the rat retina. Neuropharmacology 43 (2002) 899-909
161. Vasilaki A., Papadaki T., Notas G., Kolios G., Mastrodimou N., Hoyer D., et al. Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures. Invest Ophthalmol Vis Sci 45 (2004) 1499-1506
162. Vasilaki A., Sourlas V., Athanasiou V., Kouvaras E., and Asprodini E.K. Octreotide influences ischemia-induced [3H]D-aspartate release and GABA immunoreactivity changes in rat retinal and hippocampal preparations. FENS Abstr 4 (2008) 051.39
163. Vidwans A., Kim S., Coffin D.O., Wink D.A., and Hewet S.J. Analysis of the neuroprotective effects of varius nitric oxide donor compounds in murine mixed cortical cell culture. J Neurochem 72 (1999) 1843-1852
164. Wada M., Ogata N., Otsuji T., and Uyama M. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr Eye Res 18 (1999) 203-213
165. Watson J.C., Balster D.A., Gebhardt B.M., O'Dorisio M.S., Espenan G.D., Drouant G.J., et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 85 (2001) 266-272
166. Wilkinson-Berka J.L., Wraight C., and Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr Med Chem 13 (2006) 3307-3317
167. Wilson S.H., Davis M.I., Caballero S., and Grant M.B. Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. Growth Horm IGF Res 11 Suppl A (2001) S53-S59
168. Wise G.N. Retinal neovascularisation. Trans Am Ophthalmol Soc 54 (1956) 729-826
169. Witkovsky P. Dopamine and retinal function. D Ophthalmol 108 (2004) 17-40
170. Yi X., Mai L.C., Uyama M., and Yew D.T. Time-course expression of vascular endothelial growth factor as related to the development of the retinochoroidal vasculature in rats. Exp Brain Res 118 (1998) 155-160
171. Zalutsky R.A., and Miller R.F. The physiology of somatostatin in the rabbit retina. J Neurosci 10 (1990) 383-393
172. Zech J.C., Pouvreau I., Cotinet A., Goureau O., Le Varlet B., and de Kozak Y. Effect of cytokines and nitric oxide on tight junctions in cultured rat retinal pigment epithelium. Invest Ophthalmol Vis Sci 39 (1998) 1600-1608
173. Ziche M., Maglione D., Ribatti D., Morbidelli L., Lago C.T., Battisti M., et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 76 (1997) 517-531